Affinia Therapeutics has acquired Wilson Partners for an undisclosed amount. The transaction brings the accounting, tax, and corporate finance firm under Affinia’s ownership, with Wilson Partners’ operations set to continue as part of the larger group. The deal was finalized following regulatory approval, though no further financial terms were disclosed.
Wilson Partners serves entrepreneurs, business owners, and investors across the UK, offering tax planning, accounting, and corporate finance advice. Its client base ranges from early-stage founders to established operators seeking growth, exit, or succession strategies. Affinia Therapeutics, by contrast, operates in the biotech sector, focusing on gene therapy development. The acquisition marks a notable expansion for Affinia, which has no prior presence in professional services.
The rationale for the purchase centers on diversification. Affinia gains a stable, recurring revenue stream from Wilson Partners’ advisory work, which is less capital-intensive than drug development. For Wilson Partners, the deal provides access to Affinia’s financial resources and back-office infrastructure, allowing its team to focus on client work rather than administrative overhead. The two firms share no overlapping customers, reducing integration risk.
Wilson Partners’ existing leadership is expected to remain in place, with day-to-day client relationships unchanged. Affinia has indicated that the accounting firm will operate as a distinct unit, preserving its brand and service model. No job cuts or office closures have been announced as part of the transition.
The combined entity will now balance a high-risk, high-reward therapeutics pipeline with a steady advisory business. Whether Affinia leverages Wilson Partners’ financial expertise for internal planning or keeps the two units fully separate, the acquisition provides a cushion against the volatility inherent in biotech. The success of the deal will likely hinge on how effectively Affinia manages a business culture far removed from its core scientific focus.